Job Listings


Here are our current job openings. Please click on the job title for more information, and apply from that page if you are interested.

Use this form to perform another job search

The system cannot access your location for 1 of 2 reasons:
  1. Permission to access your location has been denied. Please reload the page and allow the browser to access your location information.
  2. Your location information has yet to be received. Please wait a moment then hit [Search] again.
Click column header to sort

Search Results Page 1 of 1

Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.  GEMTESA® is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
Project Management
ID
2022-1558
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.  GEMTESA® is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
Hidden (28081)
ID
2022-1557
Job Locations US-LA-New Orleans
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Field Sales
ID
2022-1555
Job Locations US-TN-Chattanooga
Improving quality-of-life through innovations in urology.   Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success. We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve. Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant's lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant's second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
Field Sales
ID
2022-1554
Job Locations US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.  GEMTESA® is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
CMC
ID
2022-1553
Job Locations US | US-CA-Irvine
Improving quality-of-life through innovations in urology.   Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success. We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve. Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant's lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant's second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
Market Access
ID
2022-1552
Job Locations US-CA-Irvine
Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.  GEMTESA® is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
Commercial Operations
ID
2022-1547
Job Locations US-CA-Irvine
Urovant Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions and improving the way providers and their patients confront urologic diseases that are difficult to treat.   Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   Urovant’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist approved by the U.S. FDA in December 2020 for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.  GEMTESA® is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia (OAB+BPH).   Urovant’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
Category
Quality
ID
2022-1544
Job Locations CH-Zug
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Clinical Operations
ID
2022-1541
Job Locations US-WA-Tacoma
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Field Sales
ID
2022-1539
Job Locations CH-Zug
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions. Every employee at Urovant plays an integral role to our success. We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve. Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise. The Company’s current area of research focus is Urological disease. Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy. Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Medical Affairs
ID
2022-1525
Job Locations US-LA-Baton Rouge
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Field Sales
ID
2022-1519
Job Locations US-CA-Irvine
Evergreen Requisition Territory Sales Manager - Long Term Care Overview This is an EVERGREEN career posting. Urovant Sciences is always looking to network with dynamic Sales Territory Manager talent. Our company is growing and this is a proactive way to share opportunities that often become available.  It allows jobseekers to learn more about Urovant Sciences and upload resumes if you would be interested in future opportunities.  Please visit our career page (https://urovant.com/our-culture) to learn more about all Urovant Sciences Careers.   Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.  
Category
Field Sales
ID
2021-1495
Job Locations US-CA-Irvine
Evergreen Requisition, Territory Sales Manager Improving quality-of-life through innovations in urology. Overview This is an EVERGREEN career posting. Urovant Sciences is always looking to network with dynamic Sales Territory Manager talent. Our company is growing and this is a proactive way to share opportunities that often become available.  It allows jobseekers to learn more about Urovant Sciences and upload resumes if you would be interested in future opportunities.  Please visit our career page (https://urovant.com/our-culture) to learn more about all Urovant Sciences Careers.   Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.    Every employee at Urovant plays an integral role to our success.  We are ambitious in our approach to improving outcomes for the patients and healthcare providers we serve.  Our fast-paced environment rewards strategic decision-making and collaboration, giving team members opportunities to grow beyond their expertise.   The Company’s current area of research focus is Urological disease.  Urovant Sciences is currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as an earlier stage gene-therapy for OAB in patients who have failed oral pharmacologic therapy.  Urovant Sciences, a subsidiary of Sumitovant Biopharma Ltd., intends to develop novel treatments for additional urologic diseases. Learn more at www.urovant.com.
Category
Field Sales
ID
2021-1493